ERAS
Price
$2.45
Change
+$0.02 (+0.82%)
Updated
Oct 9, 04:59 PM (EDT)
Capitalization
689.32M
27 days until earnings call
GALT
Price
$4.75
Change
+$0.01 (+0.21%)
Updated
Oct 9, 04:59 PM (EDT)
Capitalization
303.65M
39 days until earnings call
Interact to see
Advertisement

ERAS vs GALT

Header iconERAS vs GALT Comparison
Open Charts ERAS vs GALTBanner chart's image
Erasca
Price$2.45
Change+$0.02 (+0.82%)
Volume$18.03K
Capitalization689.32M
Galectin Therapeutics
Price$4.75
Change+$0.01 (+0.21%)
Volume$4.13K
Capitalization303.65M
ERAS vs GALT Comparison Chart in %
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. GALT commentary
Oct 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and GALT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 10, 2025
Stock price -- (ERAS: $2.45 vs. GALT: $4.75)
Brand notoriety: ERAS and GALT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 166% vs. GALT: 62%
Market capitalization -- ERAS: $689.32M vs. GALT: $303.65M
ERAS [@Biotechnology] is valued at $689.32M. GALT’s [@Biotechnology] market capitalization is $303.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileGALT’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • GALT’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than GALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while GALT’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 4 bearish.
  • GALT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than GALT.

Price Growth

ERAS (@Biotechnology) experienced а +15.02% price change this week, while GALT (@Biotechnology) price change was +11.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.88%. For the same industry, the average monthly price growth was +22.21%, and the average quarterly price growth was +89.30%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

GALT is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+8.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($689M) has a higher market cap than GALT($304M). GALT YTD gains are higher at: 267.442 vs. ERAS (-3.187). GALT has higher annual earnings (EBITDA): -33.52M vs. ERAS (-135.93M). ERAS has more cash in the bank: 301M vs. GALT (13.8M). ERAS has less debt than GALT: ERAS (49.4M) vs GALT (121M). ERAS (0) and GALT (0) have equivalent revenues.
ERASGALTERAS / GALT
Capitalization689M304M227%
EBITDA-135.93M-33.52M406%
Gain YTD-3.187267.442-1%
P/E RatioN/AN/A-
Revenue00-
Total Cash301M13.8M2,181%
Total Debt49.4M121M41%
FUNDAMENTALS RATINGS
GALT: Fundamental Ratings
GALT
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
69
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASGALT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYFCX75.95N/A
N/A
Rydex Financial Services C
QAMNX20.24N/A
N/A
Federated Hermes MDT Market Neutral A
OCSVX10.89N/A
N/A
Optimum Small-Mid Cap Value C
LAFTX20.94N/A
N/A
Lord Abbett Affiliated R5
JSPJX23.24N/A
N/A
Jackson Square Large-Cap Growth Inv